**Supplemental table 1:** The characteristics of NF-1 patients with malignancy

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Patient no** | **Tumor** | **Gender** | **Age at diagnosis of NF-1****(years)** | **Age at diagnosis of malignancy (years)** | **Duration of NF-1 (years)** | **Duration of tumor****(years)** | **Treatment** | **Outcome** |
| 1 | Optic glioma | M | 0,33 | 1,83 | 3,37 | 1,87 | CTX | Stable disease |
| 2 | Optic glioma | M | 9,12 | 10,25 | 1,71 | 1,75 | Follow-up  | Stable disease |
| 3 | Optic glioma | F | 10,25 | 10,25 | 0,58 | 0,58 | CTX | Unfollowed |
| 4 | Optic glioma | F | 6,75 | 9,75 | 6,25 | 3,25 | CTX | Stable disease |
| 5 | Optic glioma | M | 5,50 | 5,58 | 1,66 | 1,58 | CTX | Stable disease |
| 6 | Optic glioma | M | 8,41 | 8,50 | 1,34 | 1,25 | CTX | Partial response |
| 7 | Optic glioma | M | 0,83 | 1,41 | 2,33 | 1,75 | CTX | Partial response |
| 8 | Optic glioma | F | 3,58 | 3,58 | 7,50 | 7,50 | CTX | Progressive disease |
| 9 | Optic glioma | F | 0,25 | 3,25 | 5,41 | 2,41 | CTX | Partial response |
| 10 | Optic glioma | F | 16,5 | 16,5 | 0,58 | 0,58 | Excision+ CTX | Unfollowed |
| 11 | Brainstem glioma | F | 14,0 | 14,0 | 2,00 | 2,00 | CTX | Unfollowed |
| 12 | Brainstem glioma | M | 11,25 | 11,25 | 0,50 | 0,50 | Follow-up  | Stable disease |
| 13 | Cerebral hemispheric glioma | F | 9,75 | 9,75 | 0,16 | 0,16 | Follow-up  | Unfollowed |
| 14 | Cerebral hemispheric glioma | F | 7,16 | 7,24 | 0,08 | 0 | Follow-up | Unfollowed |
| 15 | Cerebral hemispheric glioma | F | 14,33 | 14,33 | 0,50 | 0,50 | Excision+ CTX +RTX | Died |
| 16 | Cerebral hemispheric glioma | M | 13,91 | 13,91 | 1,58 | 1,58 | Follow-up | Progressive disease |
| 17 | Cerebellar astrocytoma | F | 7,91 | 9,08 | 5,92 | 4,75 | CTX | Stable disease |
| 18 | Acute myeloid leuchemia | F | 7,50 | 7,50 | 9,90 | 9,90 | CTX | Stable disease |
| 19 | Optic glioma +Brainstem glioma | M | 8,08 | 8,08 | 2,17 | 2,17 | CTX | Stable disease |
| 20 | Optic glioma + menengioma | M | 4,00 | 4,00 | 2,16 | 2,16 | CTX | Progressive disease |
| 21 | Brainstem glioma+ cerebral hemispheric glioma | F | 14,50 | 14,50 | 0,50 | 0,50 | Follow-up  | Unfollowed |
| 22 | Cerebral hemispheric glioma + menengioma + schwannoma | M | 11,6 | 11,6 | 0,58 | 0,58 | Follow-up  | Unfollowed |
| 23 | Optic glioma + brainstem glioma+ cerebral hemispheric glioma + menegioma | F | 7,91 | 8,91 | 4,49 | 3,49 | CTX +RTX | Stable disease |

CTX: Chemotherapy, NF-1: Neurofibromatosis type 1, XRT: Radiotherapy